NCT01132547 · OUTCOME

Participant With Weight Loss ≥ 5% at the 8- Week Assessment When Compared to Baseline

Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer · Source last updated 2015-07-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Analysis population: LOCF

Groups in this outcome

Patients receive oral cyproheptadine hydrochloride twice daily for 8 weeks. cyproheptadine hydrochloride: Given orally

Patients receive an oral placebo twice daily for 8 weeks. placebo: Given orally

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Arm I Cyproheptadine Hydrochloride	9
Arm II Placebo	13

Source class 1

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I Cyproheptadine Hydrochloride	0	Not reported	Not reported	Not reported	Not reported
Arm II Placebo	2	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

groups

param Type

NUMBER

population Description

LOCF

reporting Status

POSTED

time Frame

8 weeks

title

Participant With Weight Loss ≥ 5% at the 8- Week Assessment When Compared to Baseline

type

PRIMARY

unit Of Measure

participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice